JP2019513514A - 複合細胞外マトリックス成分生体材料 - Google Patents
複合細胞外マトリックス成分生体材料 Download PDFInfo
- Publication number
- JP2019513514A JP2019513514A JP2019503607A JP2019503607A JP2019513514A JP 2019513514 A JP2019513514 A JP 2019513514A JP 2019503607 A JP2019503607 A JP 2019503607A JP 2019503607 A JP2019503607 A JP 2019503607A JP 2019513514 A JP2019513514 A JP 2019513514A
- Authority
- JP
- Japan
- Prior art keywords
- extracellular matrix
- ubm
- matrix component
- sis
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012620 biological material Substances 0.000 title claims abstract description 22
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 19
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 19
- 210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 19
- 239000002131 composite material Substances 0.000 title claims abstract description 14
- 239000010410 layer Substances 0.000 claims abstract description 48
- 239000000463 material Substances 0.000 claims abstract description 46
- 210000001519 tissue Anatomy 0.000 claims abstract description 38
- 230000000968 intestinal effect Effects 0.000 claims abstract description 10
- 239000002344 surface layer Substances 0.000 claims abstract description 10
- 210000004876 tela submucosa Anatomy 0.000 claims abstract description 10
- 239000011159 matrix material Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 16
- 210000003205 muscle Anatomy 0.000 claims description 10
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 6
- 238000003475 lamination Methods 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 210000000813 small intestine Anatomy 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 238000010297 mechanical methods and process Methods 0.000 claims 2
- 239000002639 bone cement Substances 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 7
- 230000005847 immunogenicity Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000007547 defect Effects 0.000 abstract description 6
- 210000004872 soft tissue Anatomy 0.000 abstract description 6
- 230000028709 inflammatory response Effects 0.000 abstract description 5
- 210000003195 fascia Anatomy 0.000 abstract description 4
- 210000004379 membrane Anatomy 0.000 abstract description 4
- 239000012528 membrane Substances 0.000 abstract description 4
- 210000004207 dermis Anatomy 0.000 abstract description 3
- 210000003903 pelvic floor Anatomy 0.000 abstract description 3
- 210000004224 pleura Anatomy 0.000 abstract description 3
- 210000004556 brain Anatomy 0.000 abstract description 2
- 238000011049 filling Methods 0.000 abstract description 2
- 210000004738 parenchymal cell Anatomy 0.000 abstract description 2
- 230000003014 reinforcing effect Effects 0.000 abstract description 2
- 230000013011 mating Effects 0.000 abstract 1
- 230000017423 tissue regeneration Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000008439 repair process Effects 0.000 description 8
- 210000003932 urinary bladder Anatomy 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 210000001691 amnion Anatomy 0.000 description 6
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000012292 cell migration Effects 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 206010040102 Seroma Diseases 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000011229 interlayer Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 208000021970 Abdominal wall defect Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 241000239223 Arachnida Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 108010009992 CD163 antigen Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
- A61L27/3891—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types as distinct cell layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3629—Intestinal tissue, e.g. small intestinal submucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
Description
前記中間層の層数は1〜20層である。
前記上下表層の層数はそれぞれ1〜10層である。
前記中間層と上下表層との間、中間層と上下表層内(即ち、多層UBM間、多層SIS間)は、医療用接着剤、縫合結紮、真空積層のうちの1種以上の方式で固定される。
前記生体材料は、材料を貫通する孔をさらに含む。
前記孔の直径は1〜5mmであり、孔間距離は、0.5〜5mmである。
(2)組織適合性が高く、免疫原性が低く、UBM宿主−材料境界領域での炎症応答の基本的なタイプを変えない。移植の初期段階で周囲の組織と直接接触できず、免疫応答を引き起こす可能性のある成分の放出を遅延させるように、SISは、免疫原性が非常に低いUBMに被覆され、免疫応答のタイプ及び程度が単純なUBM移植とは同じである。UBMの分解とともに、組織は、同期して増殖し、移植の後期にSISを徐々に露出しても組織修復の結果を変えない。材料全体を貫通する孔は、周囲の組織細胞の増殖を加速させ、組織液の流れに役立つため、血清腫などの局所合併症の発生率が低い。
(3)機械的強度が良好で、厚さが可変であり、異なる創傷修復のニーズに適応する。中間層は、材料全体の機械的強度を高めることができ、かつSISの層数は、異なる機械的需要がある組織修復に適応するように適切に増減することができる。医療用接着剤と真空積層との併用は、材料の剥離強度を高め、多層材料の水和又は切断後の完全性を保証し、緩めにくい。
(4)原材料の前処理の難しさを低減し、価格がひくい。本発明は、UBMとSISの利点を考慮するとともに、収量と生産サイクルの制限要因、即ち、UBMの使用量を大幅に減少させることができる。材料コストを低減し、生産サイクルを短縮し、人件費を低減する。
Claims (10)
- 無細胞小腸粘膜下組織SISを中間層とし、無細胞膀胱マトリックスUBMを上下表層とし、前記上下表層で中間層を完全に被覆してサンドイッチ構造を形成していることを特徴とする複合細胞外マトリックス成分生体材料。
- 前記SISは、機械的方法で哺乳動物の小腸の漿膜層及び筋層を除去して脱細胞化処理を行うことにより製造されることを特徴とする請求項1に記載の複合細胞外マトリックス成分生体材料。
- 前記UBMは、機械的方法で哺乳動物の膀胱の漿膜層、筋層、粘膜下組織、粘膜筋板を除去して脱細胞化処理を行うことにより製造されることを特徴とする請求項1に記載の複合細胞外マトリックス成分生体材料。
- 前記中間層の層数は1〜20層であることを特徴とする請求項1に記載の複合細胞外マトリックス成分生体材料。
- 前記上下表層の層数はそれぞれ1〜10層であることを特徴とする請求項1に記載の複合細胞外マトリックス成分生体材料。
- 前記中間層と上下表層との間、中間層と上下表層内は、医療用接着剤、縫合結紮、真空積層のうちの1種以上の方式で固定されることを特徴とする請求項1に記載の複合細胞外マトリックス成分生体材料。
- 前記医療用接着剤は、キトサン、コラーゲン、フィブリン糊、ヒアルロン酸、コンドロイチン硫酸、ヒドロゲル、骨膠、ゼラチン又はペクチンなどの成分のうちの1種以上であることを特徴とする請求項6に記載の複合細胞外マトリックス成分生体材料。
- 前記真空積層のプロセスパラメータは、真空圧力が−50〜−760mmHgであり、作用時間が0.5〜72hであることを特徴とする請求項6に記載の複合細胞外マトリックス成分生体材料。
- 前記生体材料は、材料を貫通する孔をさらに含むことを特徴とする請求項1に記載の複合細胞外マトリックス成分生体材料。
- 前記孔の直径は1〜5mmであり、孔間距離は、0.5〜5mmであることを特徴とする請求項1に記載の複合細胞外マトリックス成分生体材料。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610261472.1 | 2016-04-25 | ||
CN201610261472.1A CN105920669B (zh) | 2016-04-25 | 2016-04-25 | 一种复合细胞外基质成分生物材料 |
PCT/CN2017/073394 WO2017185853A1 (zh) | 2016-04-25 | 2017-02-13 | 一种复合细胞外基质成分生物材料 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019513514A true JP2019513514A (ja) | 2019-05-30 |
JP6827522B2 JP6827522B2 (ja) | 2021-02-10 |
Family
ID=56836273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019503607A Active JP6827522B2 (ja) | 2016-04-25 | 2017-02-13 | 複合細胞外マトリックス成分生体材料 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190314553A1 (ja) |
EP (1) | EP3443990B1 (ja) |
JP (1) | JP6827522B2 (ja) |
CN (1) | CN105920669B (ja) |
WO (1) | WO2017185853A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113908343B (zh) * | 2021-09-30 | 2023-01-20 | 卓阮医疗科技(苏州)有限公司 | 一种弯曲性能改良的生物材料 |
CN105920669B (zh) * | 2016-04-25 | 2019-03-29 | 上海卓阮医疗科技有限公司 | 一种复合细胞外基质成分生物材料 |
CN107080861B (zh) * | 2017-03-03 | 2020-01-21 | 北京博辉瑞进生物科技有限公司 | 一种高诱导活性的修复材料、制备方法和应用 |
CN107007886B (zh) * | 2017-03-03 | 2018-02-06 | 北京博辉瑞进生物科技有限公司 | 一种生物组织基质材料、制备方法及其用途 |
CN107349471A (zh) * | 2017-06-16 | 2017-11-17 | 卓阮医疗科技(苏州)有限公司 | 一种载药缓释的复合组织修复材料及其制备方法 |
CN115444993B (zh) * | 2018-06-21 | 2024-03-29 | 联邦高等教育系统匹兹堡大学 | 细胞外基质(ecm)水凝胶作为食管粘膜下流体垫的用途 |
CN114377210B (zh) * | 2020-10-19 | 2024-02-20 | 四川大学华西医院 | 一种聚氨酯/小肠粘膜下层/聚吡咯复合材料及其制备方法和用途 |
WO2022146730A1 (en) * | 2020-12-29 | 2022-07-07 | Acell, Inc. | Implantable pouch device and methods of making thereof |
CN112999430B (zh) * | 2021-04-13 | 2022-06-17 | 健诺维(成都)生物科技有限公司 | 口腔修复膜及其制备方法 |
WO2023211992A1 (en) * | 2022-04-27 | 2023-11-02 | Axogen Corporation | Sutureless connectors and methods of preparing and using same |
CN115025296A (zh) * | 2022-06-15 | 2022-09-09 | 上海新华瑞思医疗科技有限公司 | 一种引导组织再生的口腔修复膜及其制备方法和相关试剂盒 |
WO2024006421A1 (en) * | 2022-07-01 | 2024-01-04 | The Regents Of The University Of California | Method to direct vascularization of tissue grafts |
CN115814161A (zh) * | 2022-11-25 | 2023-03-21 | 深圳兰度生物材料有限公司 | 软组织修复材料及其制备方法 |
CN115970061A (zh) * | 2023-01-31 | 2023-04-18 | 上海卓阮医疗科技有限公司 | 用于缺乏血供场景的生物材料及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638312B2 (en) * | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
CA2706954A1 (en) * | 2007-11-30 | 2009-06-04 | Cook Biotech Incorporated | Expandable plugs and related delivery apparatuses and methods |
EP2310061B1 (en) * | 2008-07-01 | 2014-10-08 | Cook Biotech Incorporated | Isolated extracellular matrix material including subserous fascia |
CN101361989B (zh) * | 2008-09-03 | 2012-09-19 | 陕西瑞盛生物科技有限公司 | 双层膜状组织修补材料及其制备方法 |
CN101366979B (zh) * | 2008-09-03 | 2012-08-29 | 陕西瑞盛生物科技有限公司 | 一种组织补片及其制备方法 |
US9277999B2 (en) * | 2009-02-27 | 2016-03-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Joint bioscaffolds |
US8298586B2 (en) * | 2009-07-22 | 2012-10-30 | Acell Inc | Variable density tissue graft composition |
CN105311679A (zh) * | 2015-11-24 | 2016-02-10 | 无锡中科光远生物材料有限公司 | 一种复合疝补片及其制备方法和应用 |
CN105920669B (zh) * | 2016-04-25 | 2019-03-29 | 上海卓阮医疗科技有限公司 | 一种复合细胞外基质成分生物材料 |
-
2016
- 2016-04-25 CN CN201610261472.1A patent/CN105920669B/zh active Active
-
2017
- 2017-02-13 JP JP2019503607A patent/JP6827522B2/ja active Active
- 2017-02-13 US US16/095,633 patent/US20190314553A1/en not_active Abandoned
- 2017-02-13 WO PCT/CN2017/073394 patent/WO2017185853A1/zh active Application Filing
- 2017-02-13 EP EP17788509.2A patent/EP3443990B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2017185853A1 (zh) | 2017-11-02 |
US20190314553A1 (en) | 2019-10-17 |
EP3443990A4 (en) | 2019-05-08 |
CN105920669A (zh) | 2016-09-07 |
EP3443990A1 (en) | 2019-02-20 |
JP6827522B2 (ja) | 2021-02-10 |
CN105920669B (zh) | 2019-03-29 |
EP3443990B1 (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6827522B2 (ja) | 複合細胞外マトリックス成分生体材料 | |
KR101495281B1 (ko) | 피부 재생 또는 상처 치유를 위한 중간엽 줄기세포-하이드로겔-생분해성 또는 중간엽 줄기세포-하이드로겔-비분해성 지지체 조성물 | |
US8765468B2 (en) | Surgical device for skin therapy or testing | |
EP1375647B1 (en) | Artificial dermis and production method therefor | |
US20110293666A1 (en) | Bioengineered Tissue Constructs and Methods for Production and Use | |
US8097274B2 (en) | Skin substitutes, preparation methods and uses thereof | |
JPH01501362A (ja) | 人工マトリックスを用いる制御された細胞移植による器官のキメラ新生形態形成 | |
CN101773687B (zh) | 一种复合软组织补片的制备方法 | |
US20220054707A1 (en) | Biological material with composite extracellular matrix components | |
Singh et al. | Skin substitutes: an Indian perspective | |
CN112870445A (zh) | 一种软组织修复材料的制备方法及应用 | |
CN110404119B (zh) | 羊膜组织工程去免疫原皮肤支架的制备方法 | |
CN100479867C (zh) | 一种胶联羊膜的制备方法 | |
CN102172337B (zh) | 具有皮脂腺样结构的组织工程皮肤及其制备方法 | |
CN104971382B (zh) | 一种用无血清和牛垂体提取物培养液构建的创口贴式人工活性组织及其构建方法 | |
CN105169494A (zh) | 一种组织工程皮肤的制备方法 | |
JP3686068B2 (ja) | 皮膚の分離無細胞化方法、無細胞化真皮マトリックス及びその製造方法並びに無細胞化真皮マトリックスを用いた複合培養皮膚 | |
CN110302426B (zh) | 一种干细胞皮肤粘贴片及其制备方法和应用 | |
CN115887785B (zh) | 一种抗菌人工皮肤及其制备方法 | |
JP2005211480A (ja) | 皮膚の分離無細胞化方法、無細胞化真皮マトリックス及びその製造方法並びに無細胞化真皮マトリックスを用いた複合培養皮膚 | |
Crawford | Autografts, allografts and xenografts in cutaneous surgery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181010 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191017 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200122 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200910 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200910 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20200929 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201112 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210119 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6827522 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |